SCHEMBL20865745

SCHEMBL20865745

CC(CO)Nc1cc(Br)ccn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 5/20 0.43
PRKD1 Q15139 1/20 0.42
RIOK2 Q9BVS4 1/20 0.38
FDPS P14324 2/20 0.36
LRRK2 Q5S007 1/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
CXCR2 P25025 2/20 0.35
EGFR P00533 1/20 0.35
MAPK1 P28482 1/20 0.35
NTRK1 P04629 1/20 0.34
CCNT1 O60563 1/20 0.34
CA2 P00918 1/20 0.34
CDK1 P06493 1/20 0.34
CDK4 P11802 1/20 0.34
CCND1 P24385 1/20 0.34
CDK2 P24941 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6091366 0.81 FDPS (0.55) MAPK14PRKD1FDPSKDM4EALDH1A1
SCHEMBL26686513 0.80 SMN1; SMN2 (0.45) MAPK14RIOK2FDPSKDM4EALDH1A1
SCHEMBL15511709 0.77 CDK9 (0.47) MAPK14MEN1KMT2AEGFRMAPK1
SCHEMBL15511714 0.77 CDK9 (0.47) MAPK14MEN1KMT2AEGFRMAPK1
SCHEMBL7900357 0.75 FDPS (0.53) FDPSKDM4EALDH1A1SMN1; SMN2MEN1
SCHEMBL7893005 0.75 FDPS (0.53) FDPSKDM4EALDH1A1SMN1; SMN2MEN1
SCHEMBL15164007 0.74 FDPS (0.51) RIOK2FDPSKDM4EALDH1A1SMN1; SMN2
SCHEMBL7465452 0.74 FDPS (0.50) PRKD1FDPSKDM4EALDH1A1SMN1; SMN2
SCHEMBL4969096 0.74 FDPS (0.50) PRKD1FDPSKDM4EALDH1A1SMN1; SMN2
SCHEMBL4969090 0.74 FDPS (0.50) PRKD1FDPSKDM4EALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3702354-B1 COMPOUND HAVING ERK KINASE INHIBITORY ACTIVITY AND USE THEREOF HAIHE BIOPHARMA CO LTD (CN) 2024-05-22 EP disclosed
US-11465984-B2 Compound having ERK kinase inhibitory activity and use thereof SHANGHAI HAIHE PHARMACEUTICAL CO., LTD. (CN) 2022-10-11 US disclosed
EP-3702354-A1 COMPOUND HAVING ERK KINASE INHIBITORY ACTIVITY AND USE THEREOF Shanghai Haihe Pharmaceutical Co., Ltd. (CN) 2020-09-02 EP disclosed
EP-3702354-A1 COMPOUND HAVING ERK KINASE INHIBITORY ACTIVITY AND USE THEREOF Shanghai Haihe Pharmaceutical Co., Ltd. (CN) 2020-09-02 EP disclosed
US-20200247781-A1 COMPOUND HAVING ERK KINASE INHIBITORY ACTIVITY AND USE THEREOF HAIHE BIOPHARMA CO., LTD. (CN) 2020-08-06 US disclosed
WO-2019062949-A1 COMPOUND HAVING ERK KINASE INHIBITORY ACTIVITY AND USE THEREOF 上海海和药物研究开发有限公司 2019-04-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11465984-B2 Compound having ERK kinase inhibitory activity and use thereof MAPK1, MAPK4, MAPK7 MAPK14 38/4885PRKD1 400/4885RIOK2 197/4885
US-20200247781-A1 COMPOUND HAVING ERK KINASE INHIBITORY ACTIVITY AND USE THEREOF MAPK1, MAPK4, MAPK7 MAPK14 38/4885PRKD1 400/4885RIOK2 197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.